Abstract
We formulated de novo a poraprezinc-sodium alginate suspension (P-AG) as a specific treatment for severe gingivostomatitis and administered it to 15 patients who had developed such inflammation while on chemotherapy. Very high utility of P-AG was demonstrated and the response was classified as excellent in 10 patients and good in 5 patients. The mechanism of the beneficial effect of P-AG in treatment of severe gingivostomatitis accompanied by hemorrhagic erosion and ulcers is considered to involve the mucosal protective effect, free radical scavenging activity and tissue repair promoting action of poraprezinc together with the hemostatic action of sodium alginate.
Publication types
-
Case Reports
-
Clinical Trial
MeSH terms
-
Adult
-
Aged
-
Alginates / chemistry
-
Alginates / therapeutic use*
-
Antineoplastic Agents / therapeutic use
-
Carnosine / analogs & derivatives*
-
Carnosine / therapeutic use
-
Drug Combinations
-
Drug Compounding
-
Drug Stability
-
Female
-
Gingivitis / chemically induced
-
Gingivitis / complications
-
Gingivitis / drug therapy*
-
Glucuronic Acid
-
Hexuronic Acids
-
Humans
-
Male
-
Middle Aged
-
Neoplasms / complications*
-
Neoplasms / drug therapy
-
Organometallic Compounds / therapeutic use*
-
Stomatitis / chemically induced
-
Stomatitis / drug therapy*
-
Suspensions
-
Tongue / pathology
-
Treatment Outcome
Substances
-
Alginates
-
Antineoplastic Agents
-
Drug Combinations
-
Hexuronic Acids
-
Organometallic Compounds
-
Poraprezinc
-
Suspensions
-
Glucuronic Acid
-
Carnosine